Drug: Epogen/Aranesp
2006 sales: 4.1 B/$2.5 B
Manufacturer: Amgen
Safety concern: “black box;†heart and vascular problems at higher doses
Related Articles:
> Analyst: Anemia drug warnings 'not bad'. Report [1]
> Amgen income hammered as anemia drug use drops. Report [2]
> Amgen, J&J win a round in anemia controversy. Report [3]
> Amgen discusses the future with analysts. Report [4]
> New rules limit use of anemia drugs. Report [5]
> Amgen stock slips as anemia drug concerns rise. Report [6]
> New study points to danger of anemia drug. Report [7]
Links:
[1] http://www.fiercepharma.com/story/analyst-anemia-drug-warnings-not-bad/2007-11-09
[2] http://www.fiercebiotech.com/story/amgen-income-hammered-anemia-drug-use-drops/2007-10-26
[3] http://www.fiercebiotech.com/story/amgen-j-j-win-round-anemia-controversy/2007-09-12
[4] http://www.fiercebiotech.com/story/amgen-discusses-future-analysts/2007-09-11
[5] http://www.fiercebiotech.com/story/new-rules-limit-use-of-anemia-drugs/2007-07-31
[6] http://www.fiercebiotech.com/story/amgen-stock-slips-as-anemia-drug-concerns-rise/2007-03-02
[7] http://www.fiercebiotech.com/story/new-study-points-to-danger-of-anemia-drug/2006-11-16
[8] http://www.fiercepharma.com/special-reports/antidepressants-top-10-warnings-and-recalls-2007
[9] http://www.fiercepharma.com/special-reports/top-10-drug-warnings-and-recalls-2007
[10] http://www.fiercepharma.com/special-reports/3-zyprexa-top-10-warnings-and-recalls